 |
|
|
| |
STaR Study: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF
Has Non-Inferior Efficacy Compared to Efavirenz/Emtricitabine/Tenofovir DF and Improves Patient Reported Outcomes
|
| |
| |
Reported by Jules Levin
IAS 2013 June 30-July 3 Kuala Lumpur
C Cohen1, D Wohl2, J Arribas3, K Henry4, M Bloch5, W Towner6, H Wang7, A Shave7, S De-Oertel7, and T Fralich7
1Community Research Initiative of New England; 2University of North Carolina at Chapel Hill; 3Hospital La Paz;
4HIV Program Hennepin County Medical Center; 5Holdsworth House Medical Practice;
6Department of Infectious Disease, Kaiser Los Angeles Medical Center; 7Gilead Sciences, Inc.
Glasgow/2012: STaR Study: Single-Tablet Regimen
Emtricitabine/Rilpivirine/Tenofovir DF is Non-Inferior to
Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults Week 48 Results - (11/16/12)
Primary and Secondary Analyses of Emergent Drug Resistance through Week 48 from the STaR Study: Rilpivirine/Emtricitabine/Tenofovir DF vs. Efavirenz/Emtricitabine/Tenofovir DF Single-Tablet Regimens
http://www.natap.org/2013/ResisWksp/ResisWksp_13.htm
|
| |
|
|
|
|
|
